Tufia C. Haddad
Mayo Clinic · Mayo Clinic in Rochester
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Tufia C. Haddad as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 08:29 UTC. Open this list on ClinicalTrials.gov
- N/ANCT07810400 · A Study Of Remote Patient Monitoring (RPM) Program For Cancer Patients Initiating Cancer-directed TherapyMayo Clinic · not yet recruiting · Cancer, Lymphoma · principal investigator
- Ph4NCT06625047 · Comparing Telehealth and In-person Assessments in Glioma Patients Receiving Oral ChemotherapyMayo Clinic · completed · Astrocytoma, IDH-Mutant, Glioblastoma, Glioma · principal investigator
- Ph2NCT04294225 · Anastrozole and Letrozole After Surgery for the Treatment of Stage I-III Breast CancerMayo Clinic · completed · Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8
- Ph2NCT03179904 · TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast CancerMayo Clinic · completed · Advanced Breast Carcinoma, HER2-Positive Breast Carcinoma, Anatomic Stage III Breast Cancer AJCC v8 · principal investigator
- Ph2NCT02860000 · Alisertib With or Without Fulvestrant in Treating Patients With Locally Advanced or Metastatic, Endocrine-Resistant Breast CancerMayo Clinic · completed · Estrogen Receptor Status, HER2/Neu Negative, Invasive Breast Carcinoma · principal investigator
- Ph2NCT00684983 · Capecitabine and Lapatinib Ditosylate With or Without Cixutumumab in Treating Patients With Previously Treated HER2-Positive Stage IIIB-IV Breast CancerNational Cancer Institute (NCI) · completed · HER2 Positive Breast Carcinoma, Recurrent Breast Carcinoma, Stage IIIB Breast Cancer AJCC v7
Grants
NIH projects from RePORTER, fetched 2026-11-12 08:29 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Evaluation of a novel remote patient monitoring program for cancer patients initiating cancer-directed therapy: The SHIELD (Smart Health Integration for Early Life-saving Detection)UG3CA315308 · NCI · MAYO CLINIC ROCHESTER · fiscal years 2026 · $569,282 awarded in 2026Same name and institution; not confirmed by an ID
- Targeting Aurora-A Kinase to Overcome Endocrine Resistance in ER+ Breast CancerR01CA214893 · NCI · MAYO CLINIC ROCHESTER · fiscal years 2017 to 2021 · $315,236 awarded in 2021Grant number is on one of their registry trials
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Pathology Research Shared ResourceP30CA015083 · NCI · MAYO CLINIC ROCHESTER · PI THOMAS J FLOTTE · fiscal years 2017 to 2026Named on NCT04294225
- Project 1P50CA116201 · NCI · MAYO CLINIC ROCHESTER · PI Fergus Joseph Couch · fiscal years 2017 to 2026Named on NCT04294225
- Alliance for Clinical Trials in Oncology Member Site CoreU10CA180821 · NCI · ALLIANCE NCTN FOUNDATION · PI Evanthia Galanis · fiscal years 2017 to 2026Named on NCT00684983
- U10CA025224RePORTER returned no project for this number; it is shown as the registry gives it.Named on NCT00684983
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 08:29 UTC. The ranking covers the 200 most relevant of 13 PubMed records, and a shared surname and initials can bring in a namesake. All 13 on PubMed
- Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer.N Engl J Med · 2016456 citationsRCR 12.7
- Adaptive Randomization of Neratinib in Early Breast Cancer.N Engl J Med · 2016296 citationsRCR 7.8
- Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03).J Clin Oncol · 2022207 citationsRCR 12.6
- TBCRC 032 IB/II Multicenter Study: Molecular Insights to AR Antagonist and PI3K Inhibitor Efficacy in Patients with AR+ Metastatic Triple-Negative Breast Cancer.Clin Cancer Res · 2020136 citationsRCR 5.5
- 55 citationsRCR 4.1
- 39 citationsRCR 1.9
- Impact of BMI in Patients With Early Hormone Receptor-Positive Breast Cancer Receiving Endocrine Therapy With or Without Palbociclib in the PALLAS Trial.J Clin Oncol · 202333 citationsRCR 3.0
- Phase I trial to evaluate the addition of alisertib to fulvestrant in women with endocrine-resistant, ER+ metastatic breast cancer.Breast Cancer Res Treat · 201827 citationsRCR 0.8
- TBCRC 039: a phase II study of preoperative ruxolitinib with or without paclitaxel for triple-negative inflammatory breast cancer.Breast Cancer Res · 202422 citationsRCR 2.8
- Evaluation of continuous infusion suramin in metastatic breast cancer: impact on plasma levels of insulin-like growth factors (IGFs) and IGF-binding proteins.Clin Cancer Res · 199719 citationsRCR 0.6